Fulcrum Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Fulcrum Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11098
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a drug development company that focuses on the discovery and development of small molecule therapies to unlock the gene regulation in disease. The company’s pipeline products include Fragile X syndrome, Facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy. Its products intend to develop disease-modifying therapies for various diseases across therapeutic areas such as neurodevelopmental disorders, neuromuscular disorders, neurodegenerative disorders, central nervous system disorders and cardiovascular disorders. The company partners with biopharmaceutical companies. Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Fulcrum Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Fulcrum Therapeutics Raises USD80 Million in Series B Venture Financing 10
Fulcrum Therapeutics Raises Additional Funds through Series A Financing 12
Fulcrum Therapeutics Raises USD55 Million in Series A Financing 13
Partnerships 14
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 14
Fulcrum Therapeutics Inc – Key Competitors 15
Fulcrum Therapeutics Inc – Key Employees 16
Fulcrum Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Aug 14, 2018: Fulcrum Therapeutics promotes Diego Cadavid, M.D. to Senior Vice President, clinical development 18
Jun 27, 2018: Fulcrum Therapeutics Strengthens Board of Directors with Appointment of Kate Haviland 19
May 03, 2017: Fulcrum Therapeutics Expands Leadership Team with Appointment of Owen Wallace, Ph.D., as Chief Scientific Officer and Amit Hasija as Chief Business Officer 20
Feb 07, 2017: Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D. 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Fulcrum Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Fulcrum Therapeutics Raises USD80 Million in Series B Venture Financing 10
Fulcrum Therapeutics Raises Additional Funds through Series A Financing 12
Fulcrum Therapeutics Raises USD55 Million in Series A Financing 13
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 14
Fulcrum Therapeutics Inc, Key Competitors 15
Fulcrum Therapeutics Inc, Key Employees 16

List of Figures
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Fulcrum Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PG&E Corporation (PCG):電力:M&Aディール及び事業提携情報
    Summary PG&E Corporation (PG&E) is an energy holding company. It has interests in Pacific Gas and Electric Company. PG&E generates, transmits, and distributes electricity; and procures, transports, and stores natural gas. The company produces electricity from nuclear, hydro, fuel cell, solar, and fo …
  • Champions Oncology Inc (CSBR):製薬・医療:M&Aディール及び事業提携情報
    Summary Champions Oncology Inc (Champions), formerly Champions Biotechnology Inc, is a developer of advanced technology solutions and services to personalize the development and use of oncology drugs. The company’s technology platform is an approach based upon the implantation of primary human tumor …
  • Ora Gold Ltd (THX):企業の財務・戦略的SWOT分析
    Summary Ora Gold Ltd (Ora Gold) is a mining and mineral exploration company. The company acquires, explores and develops lead, zinc, silver, nickel, graphite, copper, gold and uranium prospects in Western Australia and the Northern Territory. Its projects include Red Bore Copper-Gold Project, Garden …
  • Codexis Inc (CDXS):製薬・医療:M&Aディール及び事業提携情報
    Summary Codexis Inc (Codexis) is a protein engineering company, which develops proteins for a wide range of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, industrial enzymes and fine chemicals, and enzymes as biotherapeutics and for use in molecular diagno …
  • Meril Life Sciences Pvt Ltd:企業の製品パイプライン分析2018
    Summary Meril Life Sciences Pvt Ltd (Meril) is a medical device company that develops and designs clinically relevant devices. The company’s product categories include cardiovascular devices, vascular interventional devices, orthopedic devices, in-vitro diagnostics devices and endo-surgery devices. …
  • The Ultimate Software Group Inc (ULTI):企業の財務・戦略的SWOT分析
    The Ultimate Software Group Inc (ULTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • WAVE Life Sciences Ltd (WVE):企業の財務・戦略的SWOT分析
    Summary WAVE Life Sciences Ltd (WAVE Life Sciences), formerly WAVE Life Sciences Pte Ltd is a genetic medicine company that develops stereopure nucleic acid therapies. The company's pipeline products comprise multiple oligonucleotide modalities such as exon-skipping and single-stranded RNAi, and ant …
  • Provogue (India) Limited (PROVOGE):企業の財務・戦略的SWOT分析
    Provogue (India) Limited (PROVOGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Metalfrio Solutions SA:企業の戦略・SWOT・財務情報
    Metalfrio Solutions SA - Strategy, SWOT and Corporate Finance Report Summary Metalfrio Solutions SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Sigma Pharmaceuticals Limited:企業の戦略・SWOT・財務情報
    Sigma Pharmaceuticals Limited - Strategy, SWOT and Corporate Finance Report Summary Sigma Pharmaceuticals Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • B. Braun Melsungen AG-製薬・医療分野:企業M&A・提携分析
    Summary B. Braun Melsungen AG (B. Braun) is a global health care company. It offers products and solutions for therapy fields and applications including acute dialysis, infusion therapy, apheresis, interventional vascular, diagnostics and treatment, cardio-thoracic surgery, laparoscopy, degenerative …
  • JAND, Inc.:医療機器:M&Aディール及び事業提携情報
    Summary JAND, Inc. (JIN), doing business a warby parker, is a manufacturing company. The company engages in operations of optical manufacturer. JIN product portfolio consists of eyeglasses, sunglasses, and gift cards. The company also manufactures and sale of eyewear for men and women. It also offer …
  • Ferno-Washington Inc:企業の戦略的SWOT分析
    Ferno-Washington Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • X4 Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary X4 Pharmaceuticals Inc (X4 Pharma) is a pharmaceutical company that develops novel therapeutics to treat cancer and rare diseases. The company’s lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiency disease. It also de …
  • Sejal Glass Limited (SEZAL):企業の財務・戦略的SWOT分析
    Sejal Glass Limited (SEZAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Sysmex America Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sysmex America Inc (Sysmex America), a subsidiary of Sysmex Corp is a medical device company that manufactures laboratory testing equipments. The company's products include clinical diagnostic devices, in vitro diagnostic hematology devices, urinalysis devices, reagents and information syste …
  • Accrol Group Holdings PLC (ACRL):企業の財務・戦略的SWOT分析
    Accrol Group Holdings PLC (ACRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Voltamp Energy SAOG (VOES):企業の財務・戦略的SWOT分析
    Voltamp Energy SAOG (VOES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Ingram Micro Inc:企業の戦略的SWOT分析
    Ingram Micro Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Companhia Energetica de Sao Paulo (CESP6)-エネルギー分野:企業M&A・提携分析
    Summary Companhia Energetica de Sao Paulo (CESP) is a state-owned integrated electric utility. It plans, constructs, and operates electric energy generation and commercialization systems. The company generates energy from hydro source. CESP owns power plants at at Rio Paran, Rio Paraibuna, and Rio J …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆